Wuxi Biologics

Wuxi Biologics's reported carbon emissions

Wuxi Biologics, a research and development company in biotechnology based in China, is committed to reducing its environmental impact. In 2024, the company reported a total of approximately 223.7 billion kg CO2e across Scope 1, 2, and 3 emissions. This breaks down to approximately 38.3 million kg CO2e for Scope 1, and approximately 160.3 million kg CO2e for Scope 2. For Scope 3 emissions in 2024, Wuxi Biologics reported approximately 2.5 million kg CO2e for business travel, approximately 19.2 million kg CO2e for employee commute, approximately 5.9 million kg CO2e for waste generated in operations, and approximately 39.5 million kg CO2e for fuel and energy-related activities. Additionally, upstream transportation and distribution accounted for approximately 2.2 million kg CO2e, and downstream transportation and distribution accounted for approximately 2.1 million kg CO2e. The company has set ambitious climate targets. Wuxi Biologics aims to reduce its Scope 1 and Scope 2 GHG emission intensity by 50% by 2030, using a 2020 base year. Furthermore, the company has committed to reducing absolute Scope 1 and Scope 2 GHG emissions by 58.8% by 2034 from a 2024 base year. Looking further ahead, Wuxi Biologics aims to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2050. In addition to Scope 1 and 2 reductions, Wuxi Biologics is also targeting its Scope 3 emissions. The company commits to reducing absolute Scope 3 GHG emissions, including those from purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting, by 90% by 2050. They also have a near-term target to reduce Scope 3 emissions related to purchased goods and services by 63.8% per kg of product produced by 2034. Wuxi Biologics has set an overall net-zero target to achieve net-zero greenhouse gas emissions across its value chain by 2050.